The Glucose Never Lies® Podcast
Host John Pemberton — diabetes educator, researcher, and dad living with type 1 since 2008 — explores how to think clearly about type 1 diabetes in the real world.
Each episode translates current evidence and expert practice into decisions you can use: CGM accuracy and interpretation, getting more from pumps and automated insulin delivery, movement as a glucose tool, nutrition that protects performance and enjoyment, sleep, travel, parties, and sport.
Guests include leading clinicians, researchers, and people with lived experience. Expect respectful challenge, plain language, and practical take-aways.
Note: Educational only. No therapeutic relationship or personal medical advice.
Buy the GNL a Coffee to keep us independent: https://www.buymeacoffee.com/jspfree2s
Email: john@theglucoseneverlies.com
The Glucose Never Lies® Podcast
Episode 34 — Building High-Performance Type 1 Diabetes Care: Technology, Targets, and Equity (Dr Peter Adolfsson)
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Suggest guests or get in contact
How do some countries consistently achieve lower HbA1c and better outcomes in type 1 diabetes while others struggle — even with the same technologies?
In this episode, John Pemberton speaks with Dr Peter Adolfsson, paediatric diabetologist in Sweden and lead author of the ISPAD 2022 Exercise Guidelines, about what actually drives population-level improvements in type 1 diabetes care.
Full show notes:
KEY TOPICS
• How Sweden’s national diabetes registry drives accountability and rapid improvement
• Why structured onboarding and early follow-up are essential for CGM and AID success
• The role of national collaboration between clinics to share best practice
• Why the highest HbA1c group should often be first in line for AID systems
• Moving toward time in tight range (3.9–7.8 mmol/L) as the next clinical target
• Equity in diabetes technology: checking subconscious bias with real data
• Why celebrating small improvements builds long-term engagement
WHAT YOU’LL LEARN
✓ Why early investment in education and follow-up changes long-term outcomes
✓ How national benchmarking between clinics improves diabetes care
✓ Why targets matter — changing what you measure changes what improves
✓ How to use AID systems strategically for people struggling with bolusing
✓ Why the first two years after diagnosis are a critical window for glycaemic outcomes
✓ The importance of psychology, social support, and multidisciplinary teams
FUTURE OF TYPE 1 DIABETES CARE
• AI-supported platforms that analyse CGM data continuously
• Clinics responding earlier when glucose control deteriorates
• Personalised therapy combining insulin with adjunct treatments (e.g., GLP-1RA)
• More flexible care models where stable patients may need fewer clinic visits
Disclaimer
This podcast is for education and informational purposes only. It does not constitute medical advice and is not a substitute for individualised care.
The Glucose Never Lies® is independent by design
We do not accept sponsorships and advertising. We operate via education grants and donations from listeners who value independence. So, consider:
Buying the GNL a Coffee:
https://www.buymeacoffee.com/jspfree2
Enquiries
Collaboration: John Pemberton — john@theglucoseneverlies.com
Creatives: Anjanee Kohli — anj@theglucoseneverlies.com
Follow The Glucose Never Lies®
Website: https://theglucoseneverlies.com/
Instagram: https://www.instagram.com/theglucoseneverlies
LinkedIn: https://www.linkedin.com/company/theglucoseneverlies
LinkedIn: John Pemberton: https://www.linkedin.com/in/john-pemberton-587104361/
X: https://twitter.com/GlucoseNLies
Disclaimer
This content is for informational purposes only and does not constitute medical advice.
© The Glucose Never Lies Ltd. All rights reserved.
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
